3,5-dimethyl-4-(2-(1-(methylsulfonyl)piperidin-4-yl)ethyl)isothiazole | 1282534-10-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: 3,5-dimethyl-4-(2-(1-(methylsulfonyl)piperidin-4-yl)ethyl)isothiazole
• CAS: 1282534-10-4
• 化学式: C₁₃H₂₂N₂O₂S₂
• 分子量: 302.462
• InChiKey: OZZGIECQLMAYCY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.36
• 重原子数：
  19.0
• 可旋转键数：
  4.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  50.27
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  3,5-dimethyl-4-(2-(1-(methylsulfonyl)piperidin-4-yl)ethyl)isothiazole 在 三甲基氯硅烷 、 羟胺 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 丙醇 为溶剂， 生成
  参考文献：
  名称：

  Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis

  摘要：

  A new achiral class of N-hydroxyformamide inhibitor of both ADAM-TS4 and ADAM-TS5, 2 has been discovered through modification of the complex P1 group present in historical inhibitors 1. This structural change improved the DMPK properties and greatly simplified the synthesis whilst maintaining excellent cross-MMP selectivity profiles. Investigation of structure-activity and structure-property relationships in the P1 group resulted in both ADAM-TS4 selective and mixed ADAM-TS4/5 inhibitors. This led to the identification of a pre-clinical candidate with excellent bioavailability across three species and predicting once daily dosing kinetics. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.028
• 作为产物：
  描述：

  1-(甲基磺酰基)-4-哌啶羧醛 在 palladium on carbon 、 potassium tert-butylate 、 氢气 作用下， 以 乙酸乙酯 为溶剂， 生成 3,5-dimethyl-4-(2-(1-(methylsulfonyl)piperidin-4-yl)ethyl)isothiazole
  参考文献：
  名称：

  Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis

  摘要：

  A new achiral class of N-hydroxyformamide inhibitor of both ADAM-TS4 and ADAM-TS5, 2 has been discovered through modification of the complex P1 group present in historical inhibitors 1. This structural change improved the DMPK properties and greatly simplified the synthesis whilst maintaining excellent cross-MMP selectivity profiles. Investigation of structure-activity and structure-property relationships in the P1 group resulted in both ADAM-TS4 selective and mixed ADAM-TS4/5 inhibitors. This led to the identification of a pre-clinical candidate with excellent bioavailability across three species and predicting once daily dosing kinetics. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.028